TKPHF — TAKEDA PHARMACEUTICAL CO LTD

—

NYSE · Health Care · Pharmaceuticals · CIK 1395064 ·

Last close

$30.47

Market Cap

$48.14B

52W High

$37.83

52W Low

$30.47

ADV30

4,857

Next earnings

2026-07-30

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

Period	Revenues	GrossProfit	OpIncome	NetIncome	Assets	Cash	Liabilities
Dec 2025	1,191,698,000,000	790,550,000,000	168,822,000,000	103,640,000,000	15,408,774,000,000	654,937,000,000	7,764,684,000,000
Sep 2025	1,112,796,000,000	732,735,000,000	68,996,000,000	-11,802,000,000	14,470,300,000,000	681,486,000,000	7,338,611,000,000
Jun 2025	1,106,685,000,000	722,010,000,000	184,565,000,000	124,243,000,000	14,004,537,000,000	350,008,000,000	7,138,357,000,000
Mar 2025	1,053,399,000,000	671,321,000,000	68,543,000,000	-103,155,000,000	14,248,344,000,000	385,113,000,000	7,312,365,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF

$1,189,062,000,000

Investing CF

$-330,806,000,000

Financing CF

$-721,117,000,000

CapEx

$-442,990,000,000

Dividends Paid

$-312,852,000,000

Buybacks

$-101,581,000,000

EPS Diluted TTM

$78.23

As of

2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings

$1,095,662,000,000

Inventory

$1,407,192,000,000

Receivables

$757,921,000,000

ST Investments

$107,004,000,000

EBIT TTM

$496,862,000,000

Pretax Income TTM

$205,369,000,000

Interest Exp TTM

$291,493,000,000

Analysts

—

Yahoo Snapshot (yfinance, live)

Total Revenue

$4,505,720,061,952

EBITDA

$1,346,403,958,784

Free Cash Flow

$356,631,117,824

Enterprise Value

$4,908,688,867,328

Total Cash

$595,053,969,408

Total Debt

$5,453,085,933,568

Shares Out

1,579,836,830

Trailing EPS

$0.77

Book Value

$30.97

ROE

2.6%

ROA

2.6%

Div Yield

4.26%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY end	Revenues	OpIncome	NetIncome	Assets	Liabilities	Equity	OCF
Mar 2025	4,581,551,000,000	486,061,000,000	107,928,000,000	14,248,344,000,000	7,312,365,000,000	—	1,057,182,000,000
Mar 2024	4,263,762,000,000	366,165,000,000	144,067,000,000	15,108,792,000,000	7,834,787,000,000	—	716,344,000,000
Mar 2023	4,027,478,000,000	587,812,000,000	317,017,000,000	13,957,750,000,000	7,603,079,000,000	—	977,156,000,000
Mar 2022	3,569,006,000,000	546,043,000,000	230,059,000,000	13,178,018,000,000	7,494,495,000,000	—	1,123,105,000,000

TTM Snapshot

Revenues TTM

—

NetIncome TTM

—

OpCashFlow TTM

—

Assets (Latest)

—

Forward EPS

$0.81

Peers — same industry

Ticker	Name	Market Cap	Last	Daily %
TAK	TAKEDA PHARMACEUTICAL CO LTD	$49.67B	$15.72	—
TEVA	TEVA PHARMACEUTICAL INDUSTRIES LTD	$40.11B	$34.45	—
ALNY	ALNYLAM PHARMACEUTICALS, INC.	$39.75B	$297.69	—
REGN	REGENERON PHARMACEUTICALS, INC.	$63.48B	$616.18	—
TEVJF	TEVA PHARMACEUTICAL INDUSTRIES LTD	$35.33B	$30.34	—

News headlines (Yahoo Finance, 1h cache)

U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease

2026-06-09 20:30 · Yahoo

EVERSANA Strengthens Commitment to Driving Market Access Growth with Addition of Industry Expert Jen Norton

2026-06-09 12:16 · Yahoo

GSK, Takeda and others notch key clinical wins in tough-to-treat diseases

2026-06-05 08:55 · Yahoo

Adlib Appoints Kristen Sauter as President & GM of Life Sciences to Accelerate Its Vertical AI Strategy

2026-06-04 12:00 · Yahoo

Otsuka showcases kidney drug data; Pfizer cuts an AI deal

2026-06-04 09:22 · Yahoo

Is Takeda Pharmaceutical Company Limited (TAK) Facing Major Legal Risk After U.S. Jury Rules on Generic Drug Delay?

2026-06-02 13:56 · Yahoo

Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading

2026-06-01 14:40 · Yahoo

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

2026-06-01 00:00 · Yahoo

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy